Publications by authors named "Miriam Sant'Angelo"
Article Synopsis
- * Researchers conducted a comprehensive literature search and analyzed 39 articles, totaling 68 reported cases, emphasizing the importance of early diagnosis and effective surgical treatment to prevent local recurrence.
- * Despite its generally good prognosis, the review stresses that appropriate care and a multidisciplinary approach can enhance patient outcomes and minimize recurrence, ultimately improving quality of life.
Article Synopsis
- Immunotherapy shows limited benefits for patients with epithelial ovarian cancer (EOC), highlighting the need to better understand local immune dynamics and pathways that suppress T-cell activity against tumors.
- The study analyzed tumor samples from 48 EOC patients to investigate the immune cell composition, focusing on tumor-infiltrating lymphocytes (TILs) using various research methods.
- Findings revealed a unique population of activated T cells in EOC tumors and identified the role of macrophages in both stimulating and inhibiting immune responses, suggesting potential targets for improving immunotherapy efficacy.
Article Synopsis
- The study aims to see how well a special imaging method called 18F-FDG PET/MRI can help figure out how bad endometrial cancer (EC) is before surgery, focusing on deep tissue invasion and lymph node involvement.
- Researchers looked at 35 patients with confirmed EC and compared the imaging results to actual tissue samples to see how accurate the imaging was.
- The results showed that 18F-FDG PET/MRI was very good at detecting lymph node issues and deep tissue invasion in most patients, making it a helpful tool for doctors in staging endometrial cancer.
Article Synopsis
- Sarcomatoid and rhabdoid renal cell carcinoma (RCC) are aggressive tumors that have not been well-defined in terms of their molecular and clinical properties.
- Emerging research shows that immune checkpoint inhibitors (ICI) may be particularly effective against these tumors, although the reasons for this are not fully understood.
- The study identifies unique molecular characteristics of S/R RCC, such as specific mutations and increased immune activity, which contribute to their aggressive nature and responsiveness to ICI treatments.
Purpose: We sought to validate levels of CD8 tumor-infiltrating cells (TIC) expressing PD-1 but not TIM-3 and LAG-3 (IF biomarker; Pignon and colleagues, 2019) and to investigate human endogenous retroviruses (hERV) as predictors of response to anti-PD-1 in a randomized trial of nivolumab (nivo) versus everolimus (evero) in patients with metastatic clear cell renal cell carcinoma (mccRCC; CheckMate-025).
Experimental Design: Tumor tissues (nivo: = 116, evero: = 107) were analyzed by multiparametric immunofluorescence (IF) and qRT-PCR. Genomic/transcriptomic analyses were performed in a subset of samples.
Article Synopsis
- Scientists studied 592 tumors from kidney cancer patients who were treated with a special medicine called PD-1 blockade to see how it worked.
- They found that the usual signs that help predict if a treatment will work, like certain gene changes, didn’t really help in this case.
- Instead, they saw that the tumors with more immune cells called CD8 T cells tended to have different genetic changes that could affect how well the treatment worked.